BioCentury | Dec 5, 2020
Product Development

Bispecifics spring ahead at this year’s ASH, SITC

...data on TCR bispecifics targeting CEA and WT1...
...receptor 7TLR8 – Toll-like receptor 8WT1Wilms tumor 1 Lauren...
BioCentury | Dec 6, 2019
Targets & Mechanisms

Bispecifics and allogeneics steal the spotlight from autologous CAR Ts

...TCR-like T cell bispecific that bivalently recognizes a peptide fragment of the Wilms tumor antigen WT1...
...CD337) - Natural killer p30 receptor PRAME - Preferentially expressed antigen in melanoma WT1 - Wilms tumor 1 Lauren...
BioCentury | Jun 14, 2019
Clinical News

June 14 Clinical Quick Takes: Chi-Med, BeiGene, UCB, Global Blood and more

Chi-Med’s surufatinib meets in Phase III for extra-pancreatic neuroendocrine tumors Hutchison China MediTech Ltd. (LSE:HCM; NASDAQ:HCM) said it is planning a pre-NDA meeting with China’s National Medical Products Administration (NMPA) after surufatinib (formerly sulfatinib) met...
BioCentury | Apr 4, 2019
Company News

Cytovant launches with Asia focus, Medigene deal

...two therapies: a preclinical T cell immunotherapy targeting NY-ESO-1, and a dendritic cell vaccine containing WT1...
...WT1/PRAME Medigene AG Roivant Sciences GmbH Sinovant Sciences Ltd. Cancer/testis antigen 1B (NY-ESO-1) (CTAG1B) Preferentially expressed antigen in melanoma (PRAME) Wilms tumor 1 (WT1) Cytovant...
BioCentury | Feb 22, 2019
Targets & Mechanisms

Solid checkpoint for CARs

PD-L1 family member B7-H3 could put CAR T cells in play for a slew of difficult-to-treat solid tumors, including pediatric cancers that lack targeted therapies, according to a pair of preclinical studies published this year....
BioCentury | Mar 15, 2018
Clinical News

Adapting T cell manufacturing methods could improve CAR Ts

Researchers at The Children's Hospital of Philadelphia identified key factors that affect the potential of T cells from pediatric patients with leukemias, lymphomas and sarcomas to be modified into effective CAR T cell therapies. The...
BioCentury | Feb 2, 2018
Product R&D

It’s the assay...

Genentech and Xenon have reported that the key to finding a selective Nav1.7 blocker is devising a better screen, not using a bigger compound library. By retooling a commonly used assay, the partners identified a...
BioCentury | Dec 15, 2017
Clinical News

Sellas reports Phase II data for galinpepimut-S in MM

...of 72-91% to the Wilms tumor 1 (WT1) peptides included in the vaccine. Immune responses against >1 WT1...
...Hamilton, Bermuda Product: Galinpepimut-S (WT1 vaccine) Business: Cancer Molecular target: Wilms tumor 1 (WT1) Description: Vaccine comprising WT1...
...safety and WT1 expression Status: Phase II data Milestone: NA Claire Quang galinpepimut-S Sellas Life Sciences Group Ltd. Wilms tumor 1 (WT1) Society...
BioCentury | Dec 14, 2017
Product R&D

Opening doors in PML

An NIH-led team has demonstrated that neutralizing antibodies can prevent infection of cells by mutant strains of JCV -- the virus responsible for the lethal brain infection PML. In a field with no clinical options,...
BioCentury | Dec 1, 2017
Company News

Sellas, Merck to collaborate on Phase I/II trial in cancer

...I/II trial of its galinpepimut-S in combination with Merck's Keytruda pembrolizumab to treat Wilms tumor-1 (WT1)-positive...
...and triple-negative breast cancers and acute myelogenous leukemia (AML). Galinpepimut-S is a vaccine comprising Wilms tumor 1 (WT1...
...& Co. Inc. (NYSE:MRK), Kenilworth, N.J. Business: Cancer Jennie Walters galinpepimut-S Keytruda Merck & Co. Inc. Sellas Life Sciences Group PD-1 Wilms tumor 1 (WT1...
Items per page:
1 - 10 of 89